A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies

December 12, 2017

In an article published this month in Human Gene Therapy, Ben Shaberman, Director of Science Communications at Foundation Fighting Blindness, writes about the Foundation's role in commercializing inherited retinal disease (IRD) gene therapies.

Beginning with the recent vision-restoring gene therapy poised for Food and Drug Administration (FDA) approval, which would be the first gene therapy to receive FDA approval for the eye or an inherited condition, Ben discusses how this groundbreaking treatment was supported by Foundation Fighting Blindness early investments.

To read the full article published in the journal, Human Gene Therapy, click here.